Drug Trial Radar · NCT02848326
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
Last checked: Nov 20, 2026Latest source record: Dec 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
834
Actual
Start
Sep 6, 2016
Primary completion
Apr 2, 2018
Study completion Apr 23, 2018
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.
Conditions
- Migraine, With or Without Aura
Interventions
AtogepantDrug
Atogepant capsule.
Placebo-matching AtogepantDrug
Placebo-matching atogepant capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment PeriodTime frame: Baseline (First 28 Days of Screening/Baseline Period) to Week 12
Locations
75 sites in 1 country. Site status is shown where the registry gives one.
Achieve Clinical Research
Birmingham, Alabama
Radiant Research, Inc.
Chandler, Arizona
The Research Center of Southern California, LLC
Carlsbad, California
Neuro-Pain Medical Center, Inc
Fresno, California
Irvine Center for Clinical Research
Irvine, California
Downtown LA Research Center, Inc.
Los Angeles, California
Excell Research
Oceanside, California
Artemis Institute for Clinical Research
San Marcos, California
Diablo Clinical Research Inc
Walnut Creek, California
Advanced Neurosciences Research
Fort Collins, Colorado
Hartford Headache Center
East Hartford, Connecticut
Associated Neurologists of Southern Connecticut, P. C.
Fairfield, Connecticut
Chase Medical Research, LLC
Waterbury, Connecticut
The George Washington University
Washington D.C., District of Columbia
Clinical Research South Florida
Coral Gables, Florida
Infinity Clinical Research
Hollywood, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Clinical Neuroscience Solutions Inc
Jacksonville, Florida
Meridien Research
Maitland, Florida
Suncoast Research
Miami, Florida
Renstar Medical Research
Ocala, Florida
Clinical Neuroscience Solutions
Orlando, Florida
Palm Beach Neurological Center / Advanced Research Consultants, Inc.
Palm Beach Gardens, Florida
Suncoast Neuroscience Associates, Inc.
St. Petersburg, Florida
Infinity Clinical Research LLC
Sunrise, Florida
Meridien Research
Tampa, Florida
Neurology Research Institute Palm Beach
West Palm Beach, Florida
Institute for Advanced Medical Research
Alpharetta, Georgia
Radiant Research
Atlanta, Georgia
Atlanta Center for Medical Research
Atlanta, Georgia
iResearch Atlanta, LLC
Decatur, Georgia
Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology
Sandy Springs, Georgia
Clinical Research Atlanta
Stockbridge, Georgia
Northwest Clinical Trials, Inc.
Boise, Idaho
Healthcare Research Network II, LLC
Blue Island, Illinois
Rowe Neurology Institute
Lenexa, Kansas
Boston Clinical Trials Inc
Boston, Massachusetts
Northeast Medical Research Associates, Inc.
North Dartmouth, Massachusetts
Medvadis Research Corporation
Watertown, Massachusetts
New England Regional Headache Center
Worcester, Massachusetts
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.